Drug intelligence / Profile preview

Program 3 (Volastra Therapeutics)

Development stage: Preclinical
Lead developer: Volastra Therapeutics

Overview

Program 3 is a preclinical-stage therapeutic program under development by Volastra Therapeutics. As part of the company's focus on chromosomal instability (CIN), the program aims to exploit specific vulnerabilities in CIN-high tumors. While Volastra has advanced other candidates like VLS-1488 and sovilnesib (KIF18A inhibitors) into clinical trials, the biological target, therapeutic modality, and specific indications for Program 3 remain undisclosed as of early 2024.

Beyond the preview

Go deeper on Program 3 (Volastra Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Program 3 (Volastra Therapeutics).

Explore the full profile